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Age and Sex Differences in Long-Term Outcomes Following
Implantable Cardioverter-Deﬁbrillator Placement in Contemporary
Clinical Practice: Findings From the Cardiovascular Research Network
Frederick A. Masoudi, MD, MSPH; Alan S. Go, MD; David J. Magid, MD, MPH; Andrea E. Cassidy-Bushrow, PhD; Jerry H. Gurwitz, MD;
Taylor I. Liu, MD, PhD; Kristi Reynolds, PhD, MPH; David H. Smith, PhD; Liza M. Reiﬂer, MPH; Karen A. Glenn, BS; Frances Fiocchi, MPH;
Robert Goldberg, PhD; Nigel Gupta, MD; Pamela N. Peterson, MD, MSPH; Claudio Schuger, MD; Humberto Vidaillet, MD;
Stephen C. Hammill, MD; Robert T. Greenlee, PhD, MPH
Background-—Patient sex and age may inﬂuence rates of death after receiving an implantable cardioverter-deﬁbrillator for primary
prevention. Differences in outcomes other than mortality and whether these differences vary by heart failure symptoms, etiology,
and left ventricular ejection fraction are not well characterized.
Methods and Results-—We studied 2954 patients with left ventricular ejection fraction ≤0.35 undergoing ﬁrst-time implantable
cardioverter-deﬁbrillator for primary prevention within the Cardiovascular Research Network; 769 patients (26%) were women, and
2827 (62%) were aged >65 years. In a median follow-up of 2.4 years, outcome rates per 1000 patient-years were 109 for death, 438
for hospitalization, and 111 for heart failure hospitalizations. Procedure-related complications occurred in 8.36%. In multivariable
models, women had signiﬁcantly lower risks of death (hazard ratio 0.67, 95% CI 0.56 to 0.80) and heart failure hospitalization (hazard
ratio 0.82, 95% CI 0.68 to 0.98) and higher risks for complications (hazard ratio 1.38, 95% CI 1.01 to 1.90) than men; patients aged
>65 years had higher risks of death (hazard ratio 1.55, 95% CI 1.30 to 1.86) and heart failure hospitalization (hazard ratio 1.25, 95% CI
1.05 to 1.49) than younger patients. Age and sex differences were generally consistent in strata according to symptoms, etiology, and
severity of left ventricular systolic dysfunction, except the higher risk of complications in women, which differed by New York Heart
Association classiﬁcation (P=0.03 for sex–New York Heart Association interaction), and the risk of heart failure hospitalization in
older patients, which differed by etiology of heart failure (P=0.05 for age–etiology interaction).
Conclusions-—The burden of adverse outcomes after receipt of an implantable cardioverter-deﬁbrillator for primary prevention is
substantial and varies according to patient age and sex. These differences in outcome generally do not vary according to baseline
heart failure characteristics. ( J Am Heart Assoc. 2015;4:e002005 doi: 10.1161/JAHA.115.002005)
Key Words: elderly • implanted cardioverter-deﬁbrillator • prognosis • women
A lthough implantable cardioverter-deﬁbrillators (ICDs) arerecommended to prevent cardiac death in selected
patients with left ventricular systolic dysfunction (LVSD),1
controversies remain about the outcomes of this therapy in
important patient subgroups, including women and elderly
patients. The clinical trials that support existing guideline
recommendations for primary-prevention ICD therapy2–4
enrolled relatively few women and patients who were younger
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than those typically seen in clinical practice.5 Studies of age
and sex differences in outcomes have focused primarily on
overall risks of death, with less attention to broader outcomes
including hospitalizations; have assessed short-term out-
comes; or have enrolled patients from single centers, limiting
generalizability.6–12 Furthermore, the published literature has
not explored the extent to which age and sex differences in
outcomes vary according to measures of heart failure
severity.
Accordingly, we studied outcomes in the Cardiovascular
Research Network (CVRN) Longitudinal Study of Implantable
Cardioverter-Deﬁbrillators (LS-ICD), a contemporary commu-
nity-based cohort receiving ICD therapy for primary prevention,
with a focus on death, hospitalization, and complications in
women and older patients. Our objectives were to characterize
the risks of adverse outcomes in this cohort; to understand sex-
and age-related differences in these outcomes; and to deter-
mine whether sex- and age-related differences vary as a
function of characteristics of heart failure, including etiology,
symptom burden, and severity of LVSD.
Methods
Data Sources
The CVRN LS-ICD has been described in detail previously.5
The data for this study were derived from 2 sources. Data on
ICD eligibility, clinical characteristics, and device and provider
details were collected from the National Cardiovascular Data
Registry (NCDR) ICD Registry, a national registry that was
formed as part of a coverage-with-evidence requirement of
the Centers for Medicare and Medicaid Services.13 The NCDR
implements a rigorous data-quality program that includes data
and range checks, outlier analysis, and random audits.14 Data
on outcomes including device-related complications, hospi-
talization, and death were obtained from the CVRN Virtual
Data Warehouse (VDW), a standardized repository of clinically
enriched administrative data generated in a distributed
fashion using identical protocols at each participating health
plan.15 Institutional review boards at participating sites
approved the study. Waiver of informed consent was obtained
because of the nature of the study. F.A.M., L.M.R., and K.A.G.
had access to and afﬁrm the accuracy of all data.
Study Cohort
We identiﬁed 3649 consecutive adult patients (aged
>18 years) undergoing ﬁrst-time ICD implantation for the
primary prevention of sudden cardiac death in 15 hospitals
within 7 integrated health systems in the CVRN between
January 1, 2006, and December 31, 2010. We excluded
patients not enrolled in 1 of the 7 CVRN health plans at the
time of implantation (n=610) and those with a left ventricular
ejection fraction (LVEF) >0.35 (n=85). The study cohort, when
compared with patients not enrolled, were older on average
(median age 69 versus 67 years, P<0.001), included a lower
proportion of women (25.8% versus 30.2%, P=0.02), were
more often white (63.0% versus 43.7%, P<0.001), and had
New York Heart Association (NYHA) I to II symptoms more
often (61.5% versus 49.3%, P<0.001).
Outcomes
The end points included time to death from any cause, time to
hospitalization from any cause and from heart failure, and
device-related complications within the ﬁrst 90 days after
implantation. Death was ascertained through the VDW, which
uses health system databases, Social Security Administration
vital status ﬁles, and state death certiﬁcate registries,
depending on the participating CVRN site. Hospitalizations
were assessed using the VDW, which includes admission and
discharge dates and diagnoses for all hospitalizations.
Because health plans are responsible for coverage of all
health services for members, hospitalizations outside of
health plan facilities are included in the VDW. Hospitalizations
for heart failure were identiﬁed using the principal discharge
diagnosis for heart failure (Table 1), an approach that has
been applied widely in studies of heart failure.16 Follow-up for
death and hospitalization was obtained through December 31,
2011, providing up to 6 years of follow-up.
Device-related complications were ascertained using a
modiﬁcation of the approach developed for purposes of
reporting complications after ICD implantation used for
hospital public reporting.17 This approach applies a variable
ascertainment time frame (either 30 or 90 days) depending
on the complication. We identiﬁed events using codes from
the International Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation; the Current Procedural Terminology; and
the Healthcare Common Procedure Coding System, in any
position on an inpatient claim (Table 1). Complications
ascertained over the ﬁrst 30 days after ICD implantation
included pneumothorax or hemothorax requiring a chest tube,
hematoma requiring transfusion or evacuation, cardiac tamp-
onade or pericardiocentesis, or death. Complications ascer-
tained over the ﬁrst 90 days included device-related infection
and mechanical complications of the ICD requiring system
revision and device reimplantation. Those patients with
incomplete follow-up data for the complications end point
(n=72) were excluded from the complications analysis.
Covariates
Patient characteristics included demographics (age, sex, and
race or ethnicity), cardiovascular history (NYHA class, LVEF,
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ischemic heart disease, nonischemic cardiomyopathy, atrial
ﬁbrillation), noncardiovascular comorbidities, laboratory val-
ues (blood urea nitrogen, hemoglobin, and creatinine) at the
time of implantation, electrocardiographic ﬁndings (QRS
morphology and duration), and device type. For the death
and hospitalization end points, we also considered the
prescription of medications for heart failure known to
inﬂuence heart failure outcomes (angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers, beta
blockers, and aldosterone antagonists) at hospital discharge.
To avoid case-wise deletion, missing values were imputed
using approaches that varied based on the proportion of
missing values. Variables were generally missing infrequently
(<2.2%); in these cases, continuous variables were imputed
using the median value of known measurements in the
population, and categorical variables were imputed as the
most common response in the population. Because QRS
morphology and QRS duration were missing more frequently
(12%), a dummy variable for missing status was used in
structuring these variables as candidates for the multivariable
models.18
Statistical Analysis
Baseline data are presented as proportions for categorical
variables and as means with SDs for continuous variables.
Comparisons of variables in sex and age strata were
performed using chi-square tests for categorical variables
and Student t tests for continuous variables. For the death
and hospitalization outcomes, crude rates of events were
calculated per 1000 person-years of follow-up with associated
95% CIs. Time-to-event analysis was performed with log-rank
tests to compare actuarial survival rates between respective
comparison groups.
Four separate multivariable models (1 per study outcome)
were constructed. Bivariate associations with P<0.20 were
included in multivariable analyses after removing any poten-
tially collinear variables. In each case, collinearity among
candidate variables was examined using eigenvalues obtained
through principal component analysis. From the principal
component results, conditional indices >3 were considered
potentially collinear. The corresponding covariates were
examined for collinearity in the multivariable model. If
including both covariates resulted in instability in estimates
or variance, the variable with the stronger bivariate associ-
ation with the outcome was retained as a candidate. For death
and the hospitalization outcomes, multivariable survival
analysis was performed using Cox proportional hazards
regression. In Cox models for death, patients were censored
at the time of last documented encounter regardless of the
continuity of health plan enrollment; for the hospitalization
outcome, patients were censored at the time of ﬁrst health
plan disenrollment or death. All multivariable models
accounted for the clustering of patients by site. For hospital-
izations, a random-site effect was included in the multivariable
Cox models. For mortality, a ﬁxed-site effect was included in
the multivariable Cox models because of lack of convergence
of a random-effects model. For complications, generalized
estimating equations were used in logistic models, with site
treated as a random effect.
In all multivariable models, age, sex, LVEF, NYHA symptom
status, and etiology of LVSD were included. To test for
variability in relationships of age and sex to these outcomes,
Table 1. ICD-9-CM, CPT, and HCPSC Codes Used to
Ascertain Clinical Events in the Cardiovascular Research
Network Virtual Data Warehouse
Clinical Event (Ascertainment
Time Frame) Codes
Heart failure hospitalization*
(3 years)
428-428.99, 398.91, 402.01, 402.11,
402.91, 404.01, 404.03, 404.11,
404.13, 404.91, 404.93
Pneumothorax/hemothorax
requiring chest tube
(30 days)
ICD-9-CM 512.x or 511.8 AND
ICD-9 Procedure 34.04, 34.05, 34.06,
or 34.09
Hematoma requiring
transfusion or evacuation
(30 days)
ICD-9-CM 998.1x, 287.4x, 518.7,
V58.2, or V59.01 AND
ICD-9 Procedure 99.00, 99.03. 99.04,
34.04, or 34.09
Tamponade or
pericardiocentesis
(30 days)
ICD-9-CM 420, 423.0, 423.3, or 423.9
AND
ICD-9-CM Procedure 37.0 or 37.12
Mechanical complication of
ICD with system revision
(90 days)
ICD-9-CM 996.0x AND
ICD-9-CM Procedure 37.75, 37.79,
37.97, 37.99, 00.52, or 37.95 OR CPT
33215, 33225, 33233, 33235, 71090,
33224, 33242
OR HCPCS C1777, C1895, C1898,
C1900, C1899, G0299, G0300
ICD Re-implantation
(90 days)
ICD-9-CM Procedure 00.52, 00.50,
00.51, 00.53, 00.54, 37.94, 37.89,
37.96, 37.98 OR
CPT 33216, 33217, 33218, 33220,
33223, 33240, 33241, 33249, 33207,
33208, 33214, 33226, 33243, 33244
OR
HCPCS C1721, C1722, C1785, C1786,
C1882, C1882
Device related infection
(90 days)
ICD-9-CM 996.61
CPT indicates Current Procedural Terminology Codes; HCPCS, Healthcare Common
Procedure Coding System; ICD-9-CM, International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation.
*To ascertain hospitalizations attributed to heart failure, only the principal discharge
diagnosis was considered.
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interaction terms between either age or sex with 3 dichot-
omous variables reﬂecting heart failure status (NYHA class I
to II versus III to IV, LVEF <0.30 versus 0.30 to 0.35, and
ischemic versus nonischemic etiology) were tested individu-
ally within the outcome models in which a signiﬁcant primary
age or sex association was identiﬁed. A 2-sided P value <0.05
was considered statistically signiﬁcant. All tests were 2-sided.
We used SAS version 9.2 and 9.3 (SAS Institute Inc) for all
analyses.
Role of the Funding Source
This study was funded by the Agency for Healthcare Research
and Quality; the National Heart, Lung, and Blood Institute of
the NIH; and the American College of Cardiology Foundation.
The study was reviewed and approved by the research and
publications committee of the NCDR ICD Registry.
Results
Study Population
The study population consisted of 2954 patients receiving an
ICD for primary prevention; 769 (26.0%) were women, and
1827 (61.8%) were aged >65 years (Table 2). Compared with
men, women were less frequently white (58.5% versus 64.3%,
P<0.001), more likely to have advanced heart failure symp-
toms (48.0% with NYHA classiﬁcation III or IV versus 35.2%,
P<0.001), less likely to have a history of atrial ﬁbrillation
(23.5% versus 35.1%, P<0.001), and less likely to have
ischemic cardiomyopathy (44.1% versus 68.5%, P<0.001).
Compared with younger patients, those aged >65 years
were more likely to have advanced heart failure symptoms
(41.2% versus 34.3%, P<0.001); were more frequently white
(68.1% versus 54.2%, P<0.001); and had a higher prevalence of
coexisting conditions, including atrial ﬁbrillation (38.0% versus
22.5%, P<0.001), hypertension (79.6% versus 63.3%, P<0.001),
and chronic lung disease (21.8% versus 16.9%, P<0.001). Older
patients were more likely to have ischemic cardiomyopathy
(70.1% versus 49.3%, P<0.001). There were no signiﬁcant
difference in age between men and women (Table 2).
Outcomes
The crude incidence rates, unadjusted risks, and adjusted
risks for adverse outcomes in the total cohort and in patients
further stratiﬁed by age and sex are shown in Table 3. The
median duration of enrollment was 2.4 years (interquartile
range 1.3 to 3.8 years). The incidence rate of death was 110
per 1000 patient-years, which was lower in women compared
with men (crude incidence 86 versus 118, adjusted hazard
ratio [HR] 0.67, 95% CI 0.56 to 0.80) and higher in patients
aged >65 years compared with younger patients (crude
incidence 133 versus 67, adjusted HR 1.55, 95% CI 1.30 to
1.86). The incidence rate of all-cause hospitalization was 438
per 1000 patient-years and did not differ signiﬁcantly
between men and women or between younger and older
patients. The incidence rate of hospitalization for heart failure
was 111 per 1000 patient-years, which was lower in women
compared with men (crude incidence rates 102 versus 115,
adjusted HR 0.82, 95% CI 0.68 to 0.98) and higher in older
compared with younger patients (crude incidence rates 127
versus 84, adjusted HR 1.25, 95% CI 1.05 to 1.49). The overall
proportion of patients who developed any device-related
complication was 8.36% and was higher in women than in
men (crude proportions 10.74% versus 7.52%, adjusted odds
ratio 1.38, 95% CI 1.01 to 1.90). With respect to individual
complications, women had a signiﬁcantly higher risk of
tamponade (1.89% versus 0.47%, P<0.001); the sex differ-
ences in risks of other complications were not statistically
signiﬁcant (Table 4). Older patients had a signiﬁcantly higher
risk of hematoma requiring evacuation or transfusion com-
pared with younger patients (1.01% versus 0.27%, P=0.03).
The rates of complications varied by device type (single lead
4.63%, dual lead 8.34%, and cardiac resynchronization
therapy–deﬁbrillator 12.20%; P<0.001) and were generally
higher in women than in men across device types, although
the device-speciﬁc differences in complications by sex were
statistically signiﬁcant among single-lead devices (Table 5).
None of the comparisons of the differences in complication
rates by device were statistically signiﬁcant between age
groups. The rates of individual complications by device type
are presented in Table 6.
Age and Sex Interactions With Measures of Heart
Failure Status
Differences in study outcomes were stratiﬁed by NYHA
symptom status, LVEF, and etiology of LVSD when the
principal age or sex relationship was signiﬁcant (Figures 1A
through 1C and 2A and 2B). The interactions between sex and
these heart failure characteristics were not statistically
signiﬁcant, with 2 exceptions. First, women had a higher risk
of complications compared with men in the stratum of
patients with NYHA I to II symptoms (women versus men: HR
1.94, 95% CI 1.26 to 3.01) versus those with III to IV
symptoms (HR 1.03, 95% CI 0.68 to 1.57; sex–NYHA
interaction, P=0.03) (Figure 1C). Second, older patients had
a higher risk of heart failure hospitalizations compared with
younger patients in the stratum of patients with ischemic
cardiomyopathy (aged >65 versus ≤65 years: HR 1.46, 95% CI
1.15 to 1.85) versus those with nonischemic cardiomyopathy
(HR 1.03, 95% CI 0.80 to 1.34; age–etiology interaction,
P=0.05) (Figure 2B).
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Table 2. Study Population Characteristics and According to Sex and Age
Characteristic Total (n=2954) Women (n=769) Men (n=2185) P Value
Age ≤65 Years
(n=1127)
Age >65 Years
(n=1827) P Value
Aged >65 years 1828 (61.9%) 473 (61.5%) 1354 (62.0%) 0.82 — —
Age, y, median (IQR) 69.0 (60.0, 75.0) 68.0 (60.0, 75.0) 69.0 (60.0, 75.0) 0.32 57.0 (51.0 to 62.0) 74.0 (70.0 to 78.0) NA
Female 769 (26.0%) — — — 296 (26.3%) 473 (25.9%) 0.82
Race/ethnicity <0.001 <0.001
White 1856 (62.8%) 450 (58.5%) 1406 (64.3%) 611 (54.2%) 1245 (68.1%)
Black 463 (15.7%) 163 (21.2%) 300 (13.7%) 231 (20.5%) 232 (12.7%)
Hispanic (not black) 438 (14.8%) 108 (14.0%) 330 (15.1%) 184 (16.3%) 254 (13.9%)
Other 197 (6.7%) 48 (6.2%) 149 (6.8%) 101 (9.0%) 96 (5.3%)
NYHA class <0.001 <0.001
I to II 1809 (61.2%) 397 (51.6%) 1412 (64.6%) 740 (65.7%) 1069 (58.5%)
III to IV 1139 (38.6%) 369 (48.0%) 770 (35.2%) 386 (34.3%) 753 (41.2%)
LVEF, % 0.62 0.12
31 to 35 431 (14.6%) 108 (14.0%) 323 (14.8%) 150 (13.3%) 281 (15.4%)
≤30 2523 (85.4%) 661 (86.0%) 1862 (85.2%) 977 (86.7%) 1546 (84.6%)
Etiology of cardiomyopathy <0.001 <0.001
Ischemic 1863 (62.2%) 339 (44.1%) 1497 (68.5%) 556 (49.3%) 1280 (70.1%)
Nonischemic 1118 (37.8%) 430 (55.9%) 688 (31.5%) 571 (50.7%) 547 (29.9%)
Atrial fibrillation 948 (32.1%) 181 (23.5%) 767 (35.1%) <0.001 254 (22.5%) 694 (38.0%) <0.001
Diabetes mellitus 1246 (42.2%) 312 (40.6%) 934 (42.7%) 0.40 459 (40.7%) 787 (43.1%) 0.43
Hypertension 2168 (73.4%) 550 (71.5%) 1618 (74.1%) 0.39 713 (63.3%) 1455 (79.6%) <0.001
Chronic lung disease 590 (20.0%) 172 (22.4%) 418 (19.1%) 0.13 191 (16.9%) 399 (21.8%) 0.004
Left bundle branch block 825 (27.9%) 318 (41.4%) 507 (23.2%) <0.001 270 (24.0%) 555 (30.4%) <0.001
QRS duration >0.12 s 1450 (49.1%) 419 (54.5%) 1031 (47.2%) <0.001 416 (36.9%) 1034 (56.6%) <0.001
Creatinine, mg/dL 1.4 (0.9) 1.2 (0.7) 1.4 (1.0) <0.001 1.3 (1.03) 1.4 (0.81) 0.015
Blood urea nitrogen, mg/dL 24.9 (13.84) 23.9 (13.65) 25.2 (13.89) 0.019 22.5 (12.99) 26.3 (14.14) <0.001
Estimated GFR, mL/min
per 1.72 m2
61.5 (22.5) 59.3 (22.9) 62.3 (22.3) 0.001 71.6 (23.9) 55.3 (19.1) <0.001
Hemoglobin, g/L <0.001 <0.001
>14.5 687 (23.3%) 56 (7.3%) 631 (28.9%) 333 (29.5%) 354 (19.4%)
13.3 to 14.5 754 (25.5%) 164 (21.3%) 590 (27.0%) 291 (25.8%) 463 (25.3%)
12.1 to 13.2 689 (23.3%) 259 (33.7%) 430 (19.7%) 241 (21.4%) 448 (24.5%)
<12.1 759 (25.7%) 276 (35.9%) 483 (22.1%) 235 (20.9%) 524 (28.7%)
Medications
ACE inhibitor or ARB 2554 (86.5%) 675 (87.8%) 1879 (86.0%) 0.21 989 (87.8%) 1565 (85.7%) 0.11
Beta blocker 2690 (91.1%) 704 (91.5%) 1986 (90.9%) 0.48 1048 (93.0%) 1642 (89.9%) 0.02
Aldosterone antagonist 994 (33.6%) 286 (37.2%) 708 (32.4%) 0.02 436 (38.7%) 558 (30.5%) <0.001
Device type <0.001 <0.001
Single chamber 955 (32.3%) 220 (28.6%) 735 (33.6%) 494 (43.8%) 461 (25.2%)
Dual chamber 1062 (36.0%) 235 (30.6%) 827 (37.8%) 352 (31.2%) 710 (38.9%)
CRT-D 937 (31.7%) 314 (40.8%) 623 (28.5%) 281 (24.9%) 656 (35.9%)
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CRT-D, cardiac resynchronization therapy with deﬁbrillator; GFR, estimated glomerular ﬁltration rate;
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
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Discussion
In this study of a community-based cohort of patients with
LVSD receiving an ICD for primary prevention, the burden of
adverse outcomes, including death and hospitalization for
heart failure over 3 years, was substantial and varied by age
and sex. After accounting for differences in other character-
istics, women had a lower risk of death and hospitalization for
heart failure than men and higher risks of device-related
complications. Older patients had higher risks of death and
heart failure–related hospitalizations but not for all-cause
hospitalizations. The age and sex differences in these
outcomes generally did not vary by severity of heart failure
symptoms, etiology of systolic dysfunction, or LVEF. The
results of this study provide estimates of the risks of several
clinically important adverse outcomes in contemporary
practice. These data can inform the decision-making process
and the design of trials of therapies in the growing population
of patients receiving ICD therapy. Furthermore, the results of
this multisite longitudinal study provide greater context for
understanding sex- and age-related differences in this high-
risk patient population.
The results of this observational study provide estimates of
the risks of adverse outcomes in a demographically diverse
population with high rates of guideline-recommended medical
therapies for LVSD receiving an ICD for primary prevention
with long-term follow-up for a wide variety of outcomes
important to patients. Although several prior studies have
Table 3. Event Rates and Risk Ratios According to Age and Sex
Event All
Sex Age, y
Women Men Risk Ratio Crude Risk Ratio Adjusted <65 ≥65 Risk Ratio Crude Risk Ratio Adjusted
Death* 110 86 118 0.73 (0.61 to 0.86) 0.67 (0.56 to 0.80) 67 133 1.91 (1.62 to 2.26) 1.55 (1.30 to 1.86)
Hospitalization
for all causes*
438 421 445 0.95 (0.86 to 1.06) 0.93 (0.83 to 1.05) 370 480 1.25 (1.13 to 1.38) 1.07 (0.96 to 1.18)
Hospitalization
for heart
failure*
111 102 114 0.91 (0.77 to 1.08) 0.82 (0.68 to 0.98) 84 127 1.41 (1.19 to 1.66) 1.25 (1.05 to 1.49)
Complications† 8.36% 10.74% 7.52% 1.43 (1.12 to 1.96) 1.38 (1.01 to 1.90) 7.15% 9.10% 1.30 (0.98 to 1.72) 1.17 (0.86 to 1.59)
Fully adjusted multivariable models included the following variables for each outcome in addition to accounting for clustering of patients by Cardiovascular Research Network site. Death:
left ventricular ejection fraction, etiology of cardiomyopathy (ischemic vs non-ischemic), New York Heart Association symptom classiﬁcation, blood urea nitrogen, atrial ﬁbrillation,
diabetes, hypertension, chronic lung disease, hemoglobin, QRS duration, ICD device type, ACE/ARB therapy, and beta blocker. All-cause hospitalization: left ventricular ejection fraction,
etiology of cardiomyopathy (ischemic vs nonischemic), New York Heart Association symptom classiﬁcation, race, atrial ﬁbrillation, diabetes, hypertension, lung disease, estimated
glomerular ﬁltration rate, blood urea nitrogen, hemoglobin, ICD device type, QRS duration, ACE/ARB therapy, and beta blocker. Heart failure hospitalization: left ventricular ejection
fraction, etiology of cardiomyopathy (ischemic vs nonischemic), New York Heart Association symptom classiﬁcation, race, atrial ﬁbrillation, diabetes, hypertension, lung disease, estimated
glomerular ﬁltration rate, blood urea nitrogen, hemoglobin, ICD device type, QRS duration, ACE/ARB therapy, and aldosterone antagonist. Complications: left ventricular ejection fraction,
etiology of cardiomyopathy (ischemic vs non-ischemic), New York Heart Association symptom classiﬁcation, atrial ﬁbrillation, diabetes, blood urea nitrogen, hemoglobin, ICD device type,
left bundle branch block, and QRS duration. ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ICD, implantable cardioverter-deﬁbrillator.
*Rates expressed as incidence per 1000 patient-years; ratios expressed as hazard ratios with 95% CIs.
†Rates expressed as proportions; ratios expressed as odds ratios with 95% CIs.
Table 4. Rates of Individual Device-Related Complications by Sex and Age
Complication Total (n=2882) Women (n=754) Men (n=2128) P Value Age ≤65 Years (n=1091) Age >65 Years (n=1791) P Value
Hematoma requiring
evacuation/transfusion*
21 (0.73%) 7 (0.93%) 14 (0.66%) 0.45 3 (0.27%) 18 (1.01%) 0.03
Tamponade* 24 (0.83%) 14 (1.89%) 10 (0.47%) <0.001 11 (1.01%) 13 (0.73%) 0.42
Death* 21 (0.73%) 6 (0.80%) 15 (0.70%) 0.80 4 (0.37%) 17 (0.95%) 0.07
Device reimplantation† 68 (2.36%) 17 (2.25%) 51 (2.40%) 0.83 23 (2.11%) 45 (2.51%) 0.49
Device-related infection† 36 (1.25%) 10 (1.33%) 26 (1.22%) 0.82 16 (1.47%) 20 (1.12%) 0.41
Mechanical complication
requiring revision†
150 (5.2%) 46 (6.10%) 104 (4.89%) 0.20 51 (4.67%) 99 (5.53%) 0.32
Any nonfatal complication 225 (7.81%) 79 (10.48%) 146 (6.86%) 0.001 75 (6.87%) 150 (8.38%) 0.15
Any complication (including
death within 30 days)
241 (8.36%) 81 (10.74%) 160 (7.52%) 0.006 78 (7.15%) 163 (9.10%) 0.07
*Ascertained over 30 days after ICD implantation.
†Ascertained over 90 days after ICD implantation.
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focused on outcomes in this population, these studies have
been limited by the lack of heterogeneity of the study
population with respect to age or sex, the lack of follow-up
beyond 1 year, and the availability of follow-up in patients
across a limited age spectrum or by the inability to
characterize outcomes other than death.6–11 The results of
this study suggest that in this diverse population of patients
with systolic dysfunction who are treated with an ICD, the
risks of adverse outcomes other than death are high,
including a substantial burden of hospitalization across
patient strata during long-term follow-up after device
implantation.
The randomized trials of ICD therapy for primary preven-
tion that underlie current guideline recommendations enrolled
younger patients and few women.2–4 Moreover, because a
number of these trials were published >2 decades ago,
therapy for patients with heart failure has evolved substan-
tially, the estimates of outcomes from these trials are of
limited value, particularly in these important demographic
groups. Although a number of observational studies have
focused on outcomes after ICD implantation, in some cases
these studies are also limited because of a lack of contem-
porary data, relatively limited follow-up, or a primary focus on
death. Because of the diversity of the CVRN cohort, we were
able to characterize sex- and age-speciﬁc risks of death,
hospitalization, and device-related complications.
Studies of sex differences in clinically meaningful long-
term outcomes after ICD placement have been conﬂicting,
perhaps in part due to differences in study design,
population, time period, and length of follow-up. Post hoc
analyses of individual randomized trials have shown variable
differences in mortality based on patient sex19–21; a meta-
analysis of the major primary prevention trials found no sex-
based differences in mortality between men and women.22
Because of the differences between the populations enrolled
in trials and those receiving ICD therapy in practice,5
observational studies provide complementary information.
Although the ﬁnding of a lower risk of death among women
in our study is similar to that of a prior single-center study of
women receiving primary-prevention devices, other studies
have found no mortality differences.7,8,12,23 Prior studies,
however, have been heterogeneous and have included
patients receiving ICDs for both primary and secondary
prevention or focused on older patients with a shorter time
frame of follow-up, possibly inﬂuencing the frequency and
correlates of adverse outcomes. The relationship between
sex and hospitalizations has not been the frequent focus of
other investigations; although a recent study from the NCDR
identiﬁed a higher risk of hospitalizations for women, this
study was conducted in an older cohort followed for
6 months and did not include cardiac resynchronization
therapy devices.12 Women have been noted to be at
Table 6. Rates of Individual Device-Related Complications Stratiﬁed by Device Type
Complication Total (n=2882) Single Lead (n=929) Dual Lead (n=1043) CRT-D (n=1005) P Value
Hematoma requiring evacuation/transfusion* 21 (0.73%) 4 (0.43%) 8 (0.77%) 9 (0.99%) 0.37
Tamponade* 24 (0.83%) 1 (0.11%) 11 (1.05%) 12 (1.32%) 0.01
Death* 21 (0.73%) 1 (0.11%) 9 (0.86%) 11 (1.21%) 0.02
Device reimplantation† 68 (2.36%) 12 (1.29%) 19 (1.82%) 37 (4.07%) <0.001
Device-related infection† 36 (1.25%) 9 (0.97%) 16 (1.53%) 11 (1.21%) 0.54
Mechanical complication requiring revision† 150 (5.2%) 26 (2.80%) 48 (4.60%) 76 (8.35%) <0.001
Any nonfatal complication 225 (7.81%) 43 (4.63%) 78 (7.48%) 104 (11.43%) <0.001
Any complication (including death within 30 days) 241 (8.36%) 43 (4.63%) 87 (8.34%) 111 (12.20%) <0.001
CRT-D indicates cardiac resynchronization therapy with deﬁbrillator.
*Ascertained over 30 days after ICD implantation.
†Ascertained over 90 days after ICD implantation.
Table 5. Rates of Device-Related Complications by Sex and Age Stratiﬁed by Device Type
Device Type Total (n=2882) Women (n=754) Men (n=2128) P Value Age ≤65 Years (n=1091) Age >65 Years (n=1791) P Value
All devices 241 (8.36%) 81 (10.74%) 160 (7.52%) 0.006 78 (7.15%) 163 (9.10%) 0.07
Single lead 43 (4.63%) 15 (6.91%) 28 (3.93%) 0.07 18 (3.79%) 25 (5.51%) 0.21
Dual lead 87 (8.34%) 23 (10.00%) 64 (7.87%) 0.30 26 (7.58%) 61 (8.71%) 0.53
CRT-D 111 (12.20%) 43 (14.01%) 68 (11.28%) 0.23 34 (12.45%) 77 (12.09%) 0.88
CRT-D indicates cardiac resynchronization therapy with deﬁbrillator.
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consistently higher risk for ICD-related complications.12,23,24
The current study provides an estimate of the magnitude of
these differences in a contemporary population, including
the differences across the spectrum of the devices com-
monly used in clinical practice.
Not surprisingly, age has been identiﬁed as an important
determinant of adverse outcomes in a wide variety of
cardiovascular conditions; however, the data generated in
this study are important because they provide contemporary
estimates of the magnitude of the age-associated risks for a
broad variety of outcomes with long-term follow-up. In a
cohort from Ontario, Canada, including patients receiving both
primary and secondary prevention ICD therapy, advanced age
A
B
C
Figure 1. Outcomes comparing women with men in strata
according to NYHA symptom status, LVEF, and etiology of left
ventricular systolic dysfunction (A, mortality; B, heart failure
hospitalization; C, complications). HR <1 indicates lower risk in
women comparedwithmen. All interaction terms are not signiﬁcant
except for the interaction between sex and NYHA in the compli-
cations model (C, P=03). HR indicates hazard ratio; LVEF, left
ventricular ejection fraction; NIDCM, nonischemic dilated cardio-
myopathy; NYHA, New York Heart Association; OR, odds ratio.
A
B
Figure 2. Outcomes comparing patients aged >65 years com-
pared with those aged ≤65 years in strata according to NYHA
symptom status, LVEF, and etiology of left ventricular systolic
dysfunction (A, mortality; B, heart failure hospitalization). HR >1
indicates a higher risk in patients aged >65 years compared with
younger patients. All interaction terms are not signiﬁcant except
for the interaction between age and etiology (nonischemic vs
ischemic) in the hospitalizations model (B, P=0.05). HR indicates
hazard ratio; LVEF, left ventricular ejection fraction; NIDCM,
nonischemic dilated cardiomyopathy; NYHA, New York Heart
Association.
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was an important risk factor for death and hospitalization.25
The death rates in that cohort were somewhat lower than in
this study. Although the cardiovascular characteristics of the
populations of our study and that from Ontario were similar,
the burden of comorbidities was greater in the CVRN cohort.
In addition, the follow-up in the current study was, on average
>1 year longer. Rates of all-cause and heart failure–related
hospitalizations were not reported in the Ontario study,
limiting comparisons with our study. Despite observed
increases in the risk of death with older age, analyses of
data from published randomized trials have not identiﬁed
clear evidence that effectiveness of ICD therapy among
eligible patients is sensitive to age.26 Nonetheless, the rates
of adverse outcomes in the demographically diverse popula-
tion of this study provide a perspective in terms of what
patients might expect after ICD implantation and emphasize
the need for additional effective therapies and treatment
strategies to reduce the longer term risks of death or
hospitalization.
Reasons for age and sex differences in outcomes after ICD
implantation are not clear. With regard to sex, proposed
mechanisms range from inherent biological differences to
differences in the severity of heart failure in patients receiving
this therapy. Some data suggest, for example, important
biological differences between men and women that could
result in lower risks of death associated with LVSD in
women.27 This sex variability could also reﬂect differences in
heart failure severity or the extent and etiology of LVSD of
patients who are selected for ICD therapy. Women, for
example, might have better survival if they have less advanced
heart failure than men when they are identiﬁed for ICD
therapy; however, in our patient cohort, this was not the case
because a higher proportion of women in the CVRN cohort
had advanced heart failure symptoms. With regard to age,
older patients may have competing causes of death that
would render ICDs less effective, especially in those with less
severe heart failure. The age and sex differences observed in
this study persisted after accounting for a wide variety of
factors and did not vary according to the burden of heart
failure symptoms, severity of LVSD, or etiology of heart
failure. Consequently, alternative explanations for these
demographic differences in outcomes warrant exploration.
Better understanding of the underlying reasons for these
differences could reﬁne the identiﬁcation of patients who
might derive maximal beneﬁt from ICD therapy.
Certain factors should be considered in the interpretation of
the results of this study. Because all patients received an ICD, it
was not possible to estimate differences in outcomes associ-
ated with the ICD therapy itself. In an observational context,
identifying suitable untreated control groups is challenging
because of the risk of substantial confounding by indication.
Nonetheless, characterizing the risks of adverse outcomes is
pertinent to the growing population of patients receiving ICD
therapy for primary prevention in contemporary practice. In
addition, the study sample was identiﬁed from integrated
health plans and thus may not be representative of some
patient populations such as the uninsured; however, the
population was demographically diverse, with robust repre-
sentation of women, racial and ethnic minorities, and elderly
patients and similar to larger US populations of patients
receiving an ICD for primary prevention.5
In this cohort study of a diverse population of patients with
LVSD receiving an ICD for primary prevention, the burden of
adverse outcomes in the 3 years following device implantation
was substantial and varied importantly by age and sex.
Observed age and sex differences were generally consistent
across the spectrum of heart failure symptoms, left ventricular
systolic function, and heart failure etiology. The risks of death,
hospitalization, and device-related complications delineated in
this study are important to the large population of patients
with LVSD who are considering ICD therapy for primary
prevention, to the clinicians caring for them, and to investi-
gators interested in understanding the risks of clinically
meaningful outcomes in the growing population of patients
receiving this potentially life-saving therapy.
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